In the United States, SLE treatment trends between 2007 and 2023 show a continued reliance on glucocorticoids, despite advances in steroid-sparing agents.
Lupus can do irreversible harm to a person's organs, damaging the lungs, kidneys, heart, liver and other vital organs through ...
Evaluation of primary aldosteronism testing in hypertensive patients with SLE in a tertiary hospital
S L E is a chronic multisystem autoimmune disease in which cardiovascular disease is a leading cause of mortality, with a ...
Recent decades have witnessed remarkable strides in the realm of clinical research and treatment for Systemic Lupus Erythematosus (SLE) and Sjögren’s ...
Recent decades have witnessed remarkable strides in the realm of clinical research and treatment for Systemic Lupus Erythematosus (SLE) and Sjögren’s ...
Allogene Therapeutics, Inc. (NASDAQ:ALLO), a biotechnology company specializing in the development of allogeneic CAR T cell therapies, stands at a critical juncture in its journey to bring innovative ...
Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to ...
Objective Combination therapy with rituximab and belimumab is a novel treatment strategy for severe SLE and lupus nephritis.
Patients with CLE who have specific patient characteristics may have lower treatment response than patients who do not have these characteristics.
Cases were identified and recruited through passive surveillance across a multicentre network. Descriptive analysis of demographic, socioeconomic and clinical characteristics at diagnosis is reported ...
Experts discuss the current research on the use of digital therapeutics for managing chronic pain in rheumatic disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback